Navigation Links
Drug Reduces Airway Mucus in Preclinical Asthma Model
Date:2/19/2008

SAN FRANCISCO, Feb. 19 /PRNewswire/ -- Inverseon, Inc. (http://www.inverseon.com) announces the publication of a rapid communication of groundbreaking research led by Professor Richard Bond of the University of Houston, Inverseon's Scientific Founder. In the March article by Nguyen, et. al., in the American Journal of Respiratory Cell and Molecular Biology 2008; 38: 256-262, entitled, "Chronic Exposure to Beta-Blockers Attenuates Inflammation and Mucin Content in a Murine Asthma Model," airway mucus hypersecretion and inflammation were almost completely reversed upon treatment with certain beta blockers. The Journal commented that, "This research may result in a paradigm shift in the treatment of asthma. This research demonstrates the importance that duration of therapy has on clinical and physiologic responses."

"It is gratifying to see these findings, which were originally described in Prof. Bond's laboratory, confirmed in a respected independent laboratory," commented William J. Garner, MD, Chairman of Inverseon.

About Inverseon, Inc.

Inverseon's product development programs target significant unmet medical needs and major market opportunities in chronic pulmonary diseases such as asthma, COPD and pulmonary hypertension. Inverseon was founded based on the original work of Prof. Richard Bond of the University of Houston. Professor Bond termed the effects "Paradoxical Pharmacology," based on the divergence of acute versus chronic effects of certain drugs in chronic diseases. For further information, please visit Inverseon's website at http://www.inverseon.com.

Forward-Looking Statement

This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

Contact:

William J. Garner, MD

bill@inverseon.com

http://www.inverseon.com

(212) 222-1188

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Inverseon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Landfill mining reduces environmental impact of growing waste
2. Landfill mining reduces environmental impact of growing waste
3. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
4. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
5. Heavier hydrogen on the atomic scale reduces friction
6. Genmab Announces Encouraging Preclinical Data for ofatumumab
7. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
8. Preclinical Research on Coronary Stent with CeloNova BioSciences Polyzene(R)- F Nanocoating Receives Award at CIRSE 2007
9. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
10. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
11. Arpida Presents Preclinical Data on AR-2474 at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , December 9, 2016 According to ... Services (Primer, Probe, Custom, Predesigned, Reagent Equipment), Application (Research, PCR, Gene, ... to 2021" published by MarketsandMarkets, the global market is expected to ... 2016, at a CAGR of 10.6% during the forecast period. ... ...
(Date:12/8/2016)... Philadelphia, PA (PRWEB) , ... December 08, 2016 ... ... fan engagement platforms, the business of innovation is taking over sports. On Thursday, ... executive will explore how technology is disrupting the playing field at a Smart ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ability ... optogenetics — is key to exciting advances in the study and mapping of ... projected via free-space optics stimulates small, transparent organisms and excites neurons within superficial ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... bioInformatics portal. In response to client demand KbioBox developed a sophisticated “3 click” ... program. Both are accessible from KBioBox’s new website, https://www.kbiobox.com/ and ...
Breaking Biology Technology:
(Date:12/6/2016)... -- Valencell , the leading innovator in performance ... third consecutive year of triple digit growth for its ... a 360 percent increase in companies who have acquired ... by sales of its wrist and ear Benchmark™ sensor ... for hearables for fitness and healthcare applications. ...
(Date:12/2/2016)... 2016 The report "Biometric Vehicle ... Technology (Iris Recognition System), Vehicle Type (Passenger Car, ... to 2021", published by MarketsandMarkets, the market is ... and is projected to grow to USD 854.8 ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/30/2016)... , Nov. 30, 2016  higi SH llc ... partnership initiative targeting national brands, industry thought-leaders and ... their respective audiences for taking steps to live ... inception in 2012, higi has built the largest ... over 38 million people who have conducted over ...
Breaking Biology News(10 mins):